CDLX CARDLYTICS, INC.
Research report · from SEC EDGAR · close 2026-07-10
$4.32 +3.8%
$248.9M mkt cap
executive summary
CARDLYTICS, INC. (CDLX) is a $248.9M company. Revenue is $233.3M (-16.2% y/y) at a -45% net margin. It is not yet profitable. Our health score is C (64/100). 1 red flag on file. Smart money is buying (1 insider, 1 funds). It funds itself; low dilution risk.
Revenue (FY)
$233.3M
-16.2% y/y
⛔Bankruptcy-risk zone
Altman Z-Score is in the distress zone (-6.56).
who's buying
Insider buys / sells
1 / 6
Cash & ST investments
$59.8M
Dilution shelf
active shelf
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-07-10 by stocktools.ai.